198 related articles for article (PubMed ID: 32340849)
1. Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population.
Ceballos-Macías José J; Rivera-Moscoso R; Flores-Real Jorge A; Vargas-Sánchez J; Ortega-Gutiérrez G; Madriz-Prado R; Velasco-Ramos PC; Muñoz-Monroy Omar E; Meneses-Pérez Anna C; Fernández-Morales Irma N; Hernández-Moreno A
Ann Endocrinol (Paris); 2020 Jun; 81(2-3):78-82. PubMed ID: 32340849
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves' orbitopathy: an observational study.
Boutzios G; Chatzi S; Goules AV; Mina A; Charonis GC; Vlachoyiannopoulos PG; Tzioufas AG
Front Endocrinol (Lausanne); 2023; 14():1186105. PubMed ID: 37424868
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab.
Moi L; Hamedani M; Ribi C
Clin Endocrinol (Oxf); 2022 Sep; 97(3):363-370. PubMed ID: 34908176
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab for the Management of Thyroid-Associated Orbitopathy.
Smith LD; Moscato EE; Seiff SR
Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):188-192. PubMed ID: 34293786
[TBL] [Abstract][Full Text] [Related]
5. Treatment of active corticosteroid-resistant graves' orbitopathy.
Pérez-Moreiras JV; Alvarez-López A; Gómez EC
Ophthalmic Plast Reconstr Surg; 2014; 30(2):162-7. PubMed ID: 24503568
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients.
Sánchez-Bilbao L; Martínez-López D; Revenga M; López-Vázquez Á; Valls-Pascual E; Atienza-Mateo B; Valls-Espinosa B; Maiz-Alonso O; Blanco A; Torre-Salaberri I; Rodríguez-Méndez V; García-Aparicio Á; Veroz-González R; Jovaní V; Peiteado D; Sánchez-Orgaz M; Tomero E; Toyos-Sáenz de Miera FJ; Pinillos V; Aurrecoechea E; Mora Á; Conesa A; Fernández-Prada M; Troyano JA; Calvo-Río V; Demetrio-Pablo R; González-Mazón Í; Hernández JL; Castañeda S; González-Gay MÁ; Blanco R
J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32878150
[TBL] [Abstract][Full Text] [Related]
7. Treatment of corticosteroid-resistant Graves' orbitopathy with tocilizumab: a single-centre prospective study.
Dorado Cortez O; Grivet D; Perrillat N; Gain P; Thuret G
Orbit; 2023 Aug; 42(4):411-417. PubMed ID: 36065465
[TBL] [Abstract][Full Text] [Related]
8. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
9. Response to tocilizumab treatment in Graves' ophthalmopathy by measuring rectus muscle thickness and chemosis using optical coherence tomography.
de-Pablo-Gómez-de-Liaño L; Fernández-Vigo JI; Troyano-Rivas J; Niño-Rueda C; Romo-López Á; Gómez-de-Liaño R
Arch Soc Esp Oftalmol (Engl Ed); 2018 Aug; 93(8):386-391. PubMed ID: 29937157
[TBL] [Abstract][Full Text] [Related]
10. Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves' orbitopathy: A five-year follow-up study.
Erdei A; Paragh G; Kovacs P; Karanyi Z; Berenyi E; Galuska L; Lenkey A; Szabados L; Gyory F; Ujhelyi B; Berta A; Boda J; Berta E; Bodor M; Gazdag A; Nagy EV
Autoimmunity; 2014 Dec; 47(8):548-55. PubMed ID: 25039242
[TBL] [Abstract][Full Text] [Related]
11. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial.
Perez-Moreiras JV; Gomez-Reino JJ; Maneiro JR; Perez-Pampin E; Romo Lopez A; Rodríguez Alvarez FM; Castillo Laguarta JM; Del Estad Cabello A; Gessa Sorroche M; España Gregori E; Sales-Sanz M;
Am J Ophthalmol; 2018 Nov; 195():181-190. PubMed ID: 30081019
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.
Maldiney T; Deschasse C; Bielefeld P
Ocul Immunol Inflamm; 2020; 28(2):281-284. PubMed ID: 30457413
[No Abstract] [Full Text] [Related]
14. Success Treatment of Severe and Active Graves' Orbitopathy with Tocilizumab After Thyroidectomy and Maximum Dose of Intravenous Methylprednisolone.
Pramono LA
Acta Med Indones; 2023 Oct; 55(4):475-477. PubMed ID: 38213047
[TBL] [Abstract][Full Text] [Related]
15. Association between Clinical Activity Score and Serum Interleukin-6, Interleukin-8 and Interleukin-10 during Systemic Glucocorticoid Treatment for Active Moderate-to-Severe Graves' Orbitopathy.
Stoynova MA; Shinkov AD; Georgiev GK; Kovatcheva RD
Curr Eye Res; 2021 Oct; 46(10):1503-1508. PubMed ID: 33849364
[No Abstract] [Full Text] [Related]
16. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
17. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
Genere N; Stan MN
Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves' Orbitopathy.
Bennedjaï A; Bouheraoua N; Gatfossé M; Dupasquier-Fediaevsky L; Errera MH; Tazartes M; Borderie V; Hennocq Q; Dellal A; Riviere S; Heron E; Fain O; Mekinian A
Ocul Immunol Inflamm; 2022 Feb; 30(2):500-505. PubMed ID: 32965148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
